Trials / Terminated
TerminatedNCT00824161
Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer
A Phase II Study of TAS-109 Given by Continuous Intravenous 14-day Infusion in Patients With Chemotherapy-refractory Advanced Colorectal Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Taiho Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate progression free survival primarily. The secondary objectives are to evaluate the antitumor activity, as assessed by objective tumor response, duration of clinical benefit, overall survival, and the safety profile of TAS-109
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAS-109 | 14-day continuous central intravenous infusion at a dose of 2.0 mg/m2/day followed by a 7-day rest period. Number of cycles: until unacceptable toxicity or disease progression requires discontinuation. |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2009-11-01
- Completion
- 2010-12-01
- First posted
- 2009-01-16
- Last updated
- 2012-04-23
- Results posted
- 2011-08-17
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00824161. Inclusion in this directory is not an endorsement.